Author: admin

Europe Garage Door Market Volume to Surge to 2.36 Million Units by 2030 as EU Housing Plan Adds 1.2 Million Homes Across 15 Major Urban Areas – Arizton

“Europe Garage Door Market Research Report by Arizton”
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025–2030.

According to Arizton latest research report, Europe garage door market is growing at a CAGR of 3.10% during 2024-2030.

 

Looking for More Information? Click: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Report Scope:

MARKET SIZE – REVENUE (2030): USD 3.20 Billion

MARKET SIZE – REVENUE (2024): USD 2.66 Billion

CAGR – REVENUE (2024-2030): 3.10%

MARKET SIZE – VOLUME (2030): 2.36 Million Units

HISTORIC YEAR: 2021-2023

BASE YEAR: 2024

FORECAST YEAR: 2025-2030

MARKET SEGMENTATION: Product Type, Material, Operation, End User, and Geography

GEOGRAPHIC ANALYSIS: North America, Europe, APAC, Latin America, and Middle East & Africa

 

Energy-Efficient Garage Doors: Europe Unexpected Sustainability Icon

The Europe garage door market is witnessing a strong shift toward energy-efficient solutions, as sustainability and energy conservation become central to construction and home improvement practices. Insulated garage doors with polyurethane or polystyrene cores and advanced weather sealing are emerging as the preferred choice, reducing heat transfer, stabilizing indoor temperatures, and lowering household energy costs.

Manufacturers such as Novoferm, with innovations like the ISO 45 Premium Plus sectional door, are aligning products with the region’s environmental objectives by combining thermal efficiency, modern aesthetics, security, and noise reduction. This positions energy-efficient garage doors not only as a sustainability-driven necessity but also as a premium lifestyle upgrade in Europe’s evolving residential market.

 

Key Developments in the European Garage Door Market

  • In April 2023, Novoferm advanced its smart integration strategy by launching a new Wi-Fi module for sectional garage doors, enabling seamless connectivity with smart home systems via a mini-USB interface.

  • In 2024, Teckentrup GmbH strengthened its European footprint by acquiring full ownership of Teckentrup UK Limited and ABC Industrial Doors Limited. This transition from joint ownership to a wholly owned subsidiary structure consolidated operational control and aligned strategic direction across its regional operations.

 

39% of UK Homes Are Smart: Garage Doors Join the Automation Wave

Smart technology integration is transforming the next phase of growth in the European garage door market, as consumers increasingly prioritize convenience, automation, and security. Leading manufacturers such as Novoferm are setting the pace with Wi-Fi modules that integrate seamlessly with Amazon Alexa, Google Home, and mediola, enabling centralized voice and app-based control. Complementary solutions from Homematic IP, Delta Dore, and retrofit devices like i-smartgate extend adoption by offering remote operation, lighting control, real-time monitoring, and smart upgrades for traditional systems.

With 39% of UK households already using smart home technologies, Europe is rapidly shifting toward modular, upgrade-ready garage door systems. This evolution not only strengthens interoperability and system efficiency but also positions the market for sustained expansion as garage doors become a critical part of the connected home ecosystem.

 

The Hidden Opportunity Behind Europe 1.6%–15% Housing Shortage

Europe housing shortage is becoming a structural driver of growth in the garage door market. In countries such as Germany, Ireland, Slovakia, Poland, Sweden, Spain, and the Netherlands, where shortages range from 1.6% to 15% of housing stock, large-scale residential expansion is creating steady downstream demand for essential building components, including garage doors. Every new housing unit, whether part of high-density urban projects with underground parking or suburban estates with detached garages, translates into fresh installation opportunities.

This surge is boosting volumes and accelerating demand for smarter, energy-efficient, and durable solutions. National initiatives, from the Netherlands’ plan to build 900,000 homes by 2030 to the UK’s £16 billion National Housing Bank, are opening long-term growth channels, making garage doors a central element of Europe’s evolving housing ecosystem.

 

UK Leads Market with USD 533M Revenue, Poland Surges Ahead

In 2024, the UK led Europe’s garage door market with revenue exceeding USD 533 million , driven by steady replacement demand, ongoing housing construction, and variable weather that boosts the need for durable, weather-resistant doors. Insulated sectional and corrosion-resistant models are gaining popularity for enhanced thermal performance and longevity.

Poland, while smaller in revenue, is projected to grow fastest in volume (CAGR >2%) thanks to expanding residential stock and infrastructure modernization. France, in contrast, shows the slowest growth among major European markets, highlighting regional differences in demand and market dynamics.

 

Book the Free Sample @: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Key Company Profiles

  • Hörmann

  • Novoferm GmbH

  • Teckentrup UK Limited

  • Garador Ltd

  • ASSA ABLOY

Other Prominent Company Profiles

  • AlluGuard

  • Alulux GmbH

  • Birkdale

  • Cedar Door

  • ERREKA

  • Gliderol Garage Doors

  • KRUŽÍK s.r.o.

  • Rundum Meir

  • RYTERNA

  • Silvelox Group SpA

  • Käuferle GmbH & Co. KG

  • SWS

  • DoorHan Group Of Companies

  • Raynor Garage Doors

  • ROMA KG

 

Market Segmentation & Forecast

Product Type

  • Sectional

  • Roller

  • Up and Over

  • Side Hinged

  • Side Sliding

Material

  • Metal

  • Wood

  • Fiberglass

  • Others

Operation

  • Manual

  • Automatic

End User

  • Residential

  • Commercial

Geography

Europe

  • United Kingdom

  • Germany

  • France

  • Italy

  • Nordic

  • Benelux

  • Spain

  • Poland

 

Other Related Reports that Might be of Your Business Requirement    

Automatic Garage Door Operator Market – Global Outlook & Forecast 2023-2028

https://www.arizton.com/market-reports/automatic-garage-door-operator-market

Europe Doors and Windows Market – Industry Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/europe-door-and-window-market

 

What Key Findings Will Our Research Analysis Reveal?    

  • How big is the Europe garage door market?

  • What is the growth rate of the Europe garage door market?

  • Which region dominates the Europe garage door market share?

  • Who are the key players in the Europe garage door market?

  • What are the significant trends in the European garage door industry?

 

Why Arizton?                                               

100% Customer Satisfaction                                               

24×7 availability – we are always there when you need us                                               

200+ Fortune 500 Companies trust Arizton’s report                                               

80% of our reports are exclusive and first in the industry                                               

100% more data and analysis                                               

1500+ reports published till date                             

                  

Post-Purchase Benefit                                           

  • 1hr of free analyst discussion                                           

  • 10% off on customization                        

                 

About Us:                                                                                    

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/europe-garage-doors-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Europe Garage Door Market Volume to Surge to 2.36 Million Units by 2030 as EU Housing Plan Adds 1.2 Million Homes Across 15 Major Urban Areas – Arizton

Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH

“Primary Ciliary Dyskinesia Clinical Trials”
DelveInsight’s, “Primary Ciliary Dyskinesia – Pipeline Insight, 2025,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Primary Ciliary Dyskinesia Pipeline constitutes 4+ key companies continuously working towards developing 4+ Primary Ciliary Dyskinesia treatment therapies, analyzes DelveInsight.

Primary Ciliary Dyskinesia Overview:

Primary ciliary dyskinesia (PCD) is an inherited autosomal recessive disorder that affects the function of tiny, hair-like structures called cilia in the respiratory tract. Dysfunctional cilia impair the clearance of mucus from the lungs, paranasal sinuses, and middle ears, resulting in recurrent respiratory infections as bacteria and irritants become trapped. Symptoms often appear shortly after birth and can include persistent coughing, choking, gagging, and neonatal respiratory distress such as lung atelectasis. People with PCD commonly experience chronic infections in the lungs, sinuses, and middle ears, along with excessive mucus production, persistent coughing, and hearing loss.

Diagnosis is typically confirmed through a lung or sinus biopsy or genetic testing, with ciliary structural abnormalities detectable via electron microscopy. Treatment aims to maintain lung function through airway clearance therapies, including regular cleaning of the sinuses and ear canals. Additional management approaches may involve antibiotics, bronchodilators, steroids, and mucolytic agents to relieve symptoms and prevent complications.

Request for a detailed insights report on Primary Ciliary Dyskinesia pipeline insights

“Primary Ciliary Dyskinesia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Ciliary Dyskinesia Therapeutics Market.

Key Takeaways from the Primary Ciliary Dyskinesia Pipeline Report

  • DelveInsight’s Primary Ciliary Dyskinesia (PCD) pipeline report highlights an active landscape, with over four companies developing more than four investigational therapies for PCD treatment.

  • Key players in this space include Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH, and others, all working to advance new treatment options and improve the therapeutic landscape. Promising pipeline candidates in various stages of development include P 1037, among others.

  • A notable development is ReCode Therapeutics’ investigational therapy, RCT1100. In June 2024, the FDA granted Orphan Drug Designation to RCT1100, recognizing its potential to address an unmet medical need. RCT1100 is an inhaled mRNA therapy designed to deliver DNAI1 mRNA to airway cells, aiming to restore normal ciliary function by correcting mutations in the DNAI1 gene, which account for roughly 7% of PCD cases. Preclinical studies have shown that RCT1100 promotes DNAI1 protein production and improves ciliary function in relevant models. ReCode is currently conducting a Phase 1 open-label trial to evaluate the safety and tolerability of single ascending doses of inhaled RCT1100 in patients with PCD caused by pathogenic DNAI1 mutations.

Primary Ciliary Dyskinesia Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Primary Ciliary Dyskinesia Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Ciliary Dyskinesia treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Primary Ciliary Dyskinesia market.

Download our free sample page report on Primary Ciliary Dyskinesia pipeline insights

Primary Ciliary Dyskinesia Emerging Drugs

  • P 1037: Parion Sciences

Primary Ciliary Dyskinesia Companies

Over four leading companies are actively working on therapies for Primary Ciliary Dyskinesia, with Parion Sciences having the most advanced candidates currently in Phase II clinical trials.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Primary Ciliary Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Primary Ciliary Dyskinesia Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Primary Ciliary Dyskinesia Therapies and Key Companies: Primary Ciliary Dyskinesia Clinical Trials and advancements

Primary Ciliary Dyskinesia Pipeline Therapeutic Assessment

• Primary Ciliary Dyskinesia Assessment by Product Type

• Primary Ciliary Dyskinesia By Stage

• Primary Ciliary Dyskinesia Assessment by Route of Administration

• Primary Ciliary Dyskinesia Assessment by Molecule Type

Download Primary Ciliary Dyskinesia Sample report to know in detail about the Primary Ciliary Dyskinesia treatment market @ Primary Ciliary Dyskinesia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Primary Ciliary Dyskinesia Current Treatment Patterns

4. Primary Ciliary Dyskinesia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Primary Ciliary Dyskinesia Late-Stage Products (Phase-III)

7. Primary Ciliary Dyskinesia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Primary Ciliary Dyskinesia Discontinued Products

13. Primary Ciliary Dyskinesia Product Profiles

14. Primary Ciliary Dyskinesia Key Companies

15. Primary Ciliary Dyskinesia Key Products

16. Dormant and Discontinued Products

17. Primary Ciliary Dyskinesia Unmet Needs

18. Primary Ciliary Dyskinesia Future Perspectives

19. Primary Ciliary Dyskinesia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Primary Ciliary Dyskinesia Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Ciliary Dyskinesia Clinical Trials, Companies, Therapies, Pipeline | Parion Sciences, ReCode Therapeutics, Translate Bio, Santhera Pharmaceuticals, ethris GmbH

Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials, Companies, Therapies, Pipeline | Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen

“Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials”
DelveInsight’s, “Extensive-Stage Small Cell Lung Cancer (ESCLC) – Pipeline Insight, 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline involves over 25 key companies actively developing more than 30 investigational therapies.

Extensive-Stage Small Cell Lung Cancer (ESCLC) Overview:

Extensive-Stage Small Cell Lung Cancer (ESCLC) is an aggressive type of lung cancer characterized by rapid progression and early spread to distant organs. Unlike non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) accounts for roughly 10–15% of all lung cancers and has a strong association with smoking. In ESCLC, the cancer has extended beyond the lungs and regional lymph nodes, commonly affecting the liver, bone marrow, brain, and adrenal glands. Patients often present with nonspecific symptoms, including persistent cough, chest pain, shortness of breath, and hemoptysis (coughing up blood). Due to widespread disease, systemic symptoms such as weight loss, fatigue, and loss of appetite are frequent. Paraneoplastic syndromes may also arise from the immune system’s response to cancer, leading to conditions like SIADH (syndrome of inappropriate antidiuretic hormone secretion), Cushing’s syndrome, or Lambert-Eaton myasthenic syndrome.

Prolonged tobacco use is the primary risk factor for ESCLC, with the likelihood of developing SCLC increasing with the intensity of smoking. The disease originates from uncontrolled growth of neuroendocrine cells in the lungs, forming rapidly expanding tumors that invade nearby tissues and metastasize early. Genetic alterations in tumor suppressor genes such as TP53 and RB1 are commonly linked to SCLC development.

Request for a detailed insights report on Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline insights

“Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapeutics Market.

Key Takeaways from the Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Report

  • DelveInsight’s Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report highlights a dynamic landscape, with over 25 companies actively developing more than 30 investigational therapies for ESCLC treatment.

  • Key players in this space include Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC, and others, all working to advance new treatment options for ESCLC. Promising pipeline candidates in various stages of development include Serplulimab combined with chemotherapy, Vobramitamab duocarmazine (MGC018), RYZ101, among others.

  • In October 2024, Zai Lab reported promising results for its antibody-drug conjugate, ZL-1310, in ESCLC. Among 19 evaluable patients, 74% responded to treatment, with nine responses still awaiting confirmation. The company plans to optimize dosing between late 2024 and early 2025.

  • Additionally, on May 16, 2024, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra) for patients with ES-SCLC who progressed following platinum-based chemotherapy. This approval was supported by a study showing a 40% overall response rate, with a median duration of response of 9.7 months. Notably, patients with platinum-resistant SCLC achieved a 52% response rate. Common side effects included cytokine release syndrome, fatigue, and nausea.

Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Extensive-Stage Small Cell Lung Cancer (ESCLC) Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Extensive-Stage Small Cell Lung Cancer (ESCLC) market.

Download our free sample page report on Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline insights

Extensive-Stage Small Cell Lung Cancer (ESCLC) Emerging Drugs

  • Serplulimab+Chemo: Shanghai Henlius Biotech

  • Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.

  • RYZ101: RayzeBio, Inc.

Extensive-Stage Small Cell Lung Cancer (ESCLC) Companies

Over 25 leading companies are actively working on therapies for Extensive-Stage Small Cell Lung Cancer (ESCLC), with Shanghai Henlius Biotech having the most advanced candidate currently in Phase III clinical trials.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Extensive-Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Extensive-Stage Small Cell Lung Cancer (ESCLC) Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapies and Key Companies: Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials and advancements

Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Therapeutic Assessment

• Extensive-Stage Small Cell Lung Cancer (ESCLC) Assessment by Product Type

• Extensive-Stage Small Cell Lung Cancer (ESCLC) By Stage

• Extensive-Stage Small Cell Lung Cancer (ESCLC) Assessment by Route of Administration

• Extensive-Stage Small Cell Lung Cancer (ESCLC) Assessment by Molecule Type

Download Extensive-Stage Small Cell Lung Cancer (ESCLC) Sample report to know in detail about the Extensive-Stage Small Cell Lung Cancer (ESCLC) treatment market @ Extensive-Stage Small Cell Lung Cancer (ESCLC) Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Extensive-Stage Small Cell Lung Cancer (ESCLC) Current Treatment Patterns

4. Extensive-Stage Small Cell Lung Cancer (ESCLC) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Extensive-Stage Small Cell Lung Cancer (ESCLC) Late-Stage Products (Phase-III)

7. Extensive-Stage Small Cell Lung Cancer (ESCLC) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Extensive-Stage Small Cell Lung Cancer (ESCLC) Discontinued Products

13. Extensive-Stage Small Cell Lung Cancer (ESCLC) Product Profiles

14. Extensive-Stage Small Cell Lung Cancer (ESCLC) Key Companies

15. Extensive-Stage Small Cell Lung Cancer (ESCLC) Key Products

16. Dormant and Discontinued Products

17. Extensive-Stage Small Cell Lung Cancer (ESCLC) Unmet Needs

18. Extensive-Stage Small Cell Lung Cancer (ESCLC) Future Perspectives

19. Extensive-Stage Small Cell Lung Cancer (ESCLC) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Extensive-Stage Small Cell Lung Cancer (ESCLC) Clinical Trials, Companies, Therapies, Pipeline | Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen

Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith

“Amyotrophic Lateral Sclerosis Clinical Trials”
DelveInsight’s, “Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing more than 80 investigational therapies.

Amyotrophic Lateral Sclerosis Overview:

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative condition that targets motor neurons. Its development involves both hereditary and sporadic factors, although no single cause has been definitively established. ALS affects both upper and lower motor neurons, often beginning with lower motor neuron degeneration in the proximal limbs, and gradually progresses to paralysis, ultimately resulting in death.

While several mechanisms have been suggested, the precise cause of sporadic ALS remains unclear. Contributing factors may include disruptions in RNA processing that promote prion-like aggregation, mutations in the superoxide dismutase 1 (SOD1) gene causing free radical toxicity, inflammatory processes, and elevated glutamate levels. Familial ALS, a less common form, is frequently associated with genetic mutations—most notably the C9ORF72 repeat expansion and SOD1 mutations. Misfolded SOD1 proteins aggregate toxically, leading to cellular damage and apoptosis, with these mutations typically inherited in an autosomal dominant pattern.

Overall, ALS is a complex disorder with multiple contributing factors rather than a single origin, resulting in a multifactorial and heterogeneous pathogenesis.

Request for a detailed insights report on Amyotrophic Lateral Sclerosis pipeline insights

“Amyotrophic Lateral Sclerosis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Amyotrophic Lateral Sclerosis Therapeutics Market.

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

  • DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.

  • Key Amyotrophic Lateral Sclerosis companies such as AIonis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others are evaluating new drugs for Amyotrophic Lateral Sclerosis to improve the treatment landscape.

  • Promising Amyotrophic Lateral Sclerosis pipeline therapies in various stages of development include MN-166, RNS60, VM202, QRL-201, and others.

  • Celosia Therapeutics, a biotech startup from Macquarie University, has secured funding to advance CTX-1000, a potential disease-modifying therapy targeting the TDP-43 protein implicated in ALS pathology. Preclinical studies have shown promise, and human trials are anticipated to commence by late 2025.

  • In April 2023, the FDA approved Qalsody for patients with ALS associated with mutations in the superoxide dismutase 1 (SOD1) gene. Qalsody is an antisense oligonucleotide designed to reduce the synthesis of the SOD1 protein, addressing a specific genetic subset of ALS. The approval was based on observed reductions in plasma neurofilament light (NfL), a biomarker indicative of neuronal injury and degeneration.

Amyotrophic Lateral Sclerosis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Amyotrophic Lateral Sclerosis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

Download our free sample page report on Amyotrophic Lateral Sclerosis pipeline insights

Amyotrophic Lateral Sclerosis Emerging Drugs

  • MN-166: MediciNova

  • RNS60: Revalesio

  • VM202: Helixmith

  • QRL-201: QurAlis Corporation

Amyotrophic Lateral Sclerosis Companies

Over 75 leading companies are actively developing therapies for Amyotrophic Lateral Sclerosis (ALS), with MediciNova having the most advanced candidates currently in Phase II/III clinical trials.

DelveInsight’s report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Amyotrophic Lateral Sclerosis Therapies and Key Companies: Amyotrophic Lateral Sclerosis Clinical Trials and advancements

Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type

• Amyotrophic Lateral Sclerosis By Stage

• Amyotrophic Lateral Sclerosis Assessment by Route of Administration

• Amyotrophic Lateral Sclerosis Assessment by Molecule Type

Download Amyotrophic Lateral Sclerosis Sample report to know in detail about the Amyotrophic Lateral Sclerosis treatment market @ Amyotrophic Lateral Sclerosis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Amyotrophic Lateral Sclerosis Current Treatment Patterns

4. Amyotrophic Lateral Sclerosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Amyotrophic Lateral Sclerosis Late-Stage Products (Phase-III)

7. Amyotrophic Lateral Sclerosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Amyotrophic Lateral Sclerosis Discontinued Products

13. Amyotrophic Lateral Sclerosis Product Profiles

14. Amyotrophic Lateral Sclerosis Key Companies

15. Amyotrophic Lateral Sclerosis Key Products

16. Dormant and Discontinued Products

17. Amyotrophic Lateral Sclerosis Unmet Needs

18. Amyotrophic Lateral Sclerosis Future Perspectives

19. Amyotrophic Lateral Sclerosis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Amyotrophic Lateral Sclerosis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith

Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Years | DelveInsight’s Perspective on Market Impact, Competitive Landscape and Other Pipeline Therapies

“Fibromyalgia Market Insight, Epidemiology and Market Forecast report”
DelveInsight Business Research’s latest report highlights the transformative impact of the FDA’s approval of TONMYA (cyclobenzaprine HCl sublingual tablets) by Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP). This landmark approval marks the first new fibromyalgia treatment approved by the FDA in more than 15 years, offering new hope for millions of patients suffering from this debilitating chronic pain condition.

Key Fibromyalgia Market Highlights

  • TONMYA’s approval is expected to be a key driver of the fibromyalgia treatment market growth, given its first-in-class status and differentiated therapeutic approach.

  • Fibromyalgia has a mean prevalence of 2.7% worldwide, with significant age and gender disparity.

  • Fibromyalgia Companies: Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Sanofi S.A. (NASDAQ: SNY), AstraZeneca PLC (NASDAQ: AZN), Abbott Laboratories (NYSE: ABT), GlaxoSmithKline PLC (NYSE: GSK), Amgen Inc. (NASDAQ: AMGN), Viatris Inc. (NASDAQ: VTRS), and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Exagen Inc. (NASDAQ: XGN), Dogwood Therapeutics, Inc. (NASDAQ: DWTX), among others.

Market Impact and Fibromyalgia Patient Population

According to DelveInsight’s Fibromyalgia Market Insight, Epidemiology and Market Forecast report, fibromyalgia represents a significant global health burden with a mean prevalence of 2.7% worldwide, showing regional variations with higher rates in America compared to Europe. In the United States, the condition affects approximately 2% of the general population, with a pronounced gender disparity where women are disproportionately affected, representing approximately 80% of total diagnosed cases.

The condition is characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive dysfunction, significantly impacting patients’ quality of life. It is the leading cause of generalized musculoskeletal pain in women and represents a significant economic burden, with annual costs estimated at over $9 billion in the United States alone.

Furthermore, the report highlights that the fibromyalgia treatment market is projected to grow at a significant CAGR. TONMYA’s approval is expected to be a key driver of this growth trajectory, given its first-in-class status and differentiated therapeutic approach.

Download the Fibromyalgia Market report to understand which other factors are driving the therapeutic market @ Fibromyalgia Market Trends.

TONMYA Treatment Approach

TONMYA represents a first-in-class, non-opioid analgesic designed for once-daily bedtime administration. The sublingual formulation allows for rapid absorption into the bloodstream while avoiding first-pass hepatic metabolism, potentially reducing the formation of long-lasting metabolites associated with traditional oral cyclobenzaprine formulations.

“The TONMYA approval addresses a critical unmet medical need in fibromyalgia treatment,” said Seth Lederman, M.D., CEO of Tonix Pharmaceuticals. “At Tonix, we recognized the transformative potential of pursuing a new approach with TONMYA for fibromyalgia, a chronic overlapping pain condition that has gone without innovation for many years.”

TONMYA Clinical Validation and Efficacy

The TONMYA FDA approval was based on robust clinical evidence from two pivotal Phase 3 trials (RELIEF and RESILIENT) involving nearly 1,000 fibromyalgia patients. Key clinical outcomes include a statistically significant reduction in daily pain scores versus placebo at 14 weeks (primary endpoint), with a greater percentage of patients experiencing clinically meaningful (≥30%) pain improvement after 3 months.

Fibromyalgia Competitive Landscape and Market Positioning

TONMYA, which is expected to be commercially available in the fourth quarter of 2025, enters a highly competitive fibromyalgia treatment landscape that has been dominated by three FDA-approved therapies for over 15 years: LYRICA (pregabalin) by Pfizer Inc., which historically commands the largest market share; CYMBALTA (duloxetine) by Eli Lilly and Company; and SAVELLA (milnacipran), now available through multiple generic manufacturers.

The broader competitive ecosystem includes established pharmaceutical giants such as Johnson & Johnson, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Amgen Inc., Viatris Inc., and Teva Pharmaceutical Industries Ltd., which compete through off-label prescribing of pain management and antidepressant medications.

Explore the Fibromyalgia Drug Battle: TONMYA vs. LYRICA vs. CYMBALTA vs. SAVELLA. Discover how these breakthrough Fibromyalgia therapies compare in efficacy, safety, cost, and market impact @ Fibromyalgia Drugs Market

Emerging Fibromyalgia Pipeline Therapies

Several companies are actively developing next-generation fibromyalgia therapies, including Aptinyx Inc. with NMDA receptor modulator programs, Prismic Pharmaceuticals Inc. focusing on novel pain pathways, Scilex Holding advancing non-opioid analgesics, Tryptamine Therapeutics exploring psychedelic-assisted therapies, and Intec Pharma Ltd. developing gastroretentive drug delivery systems.

Furthermore, regional players such as Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited compete primarily in the generic space. Despite this crowded landscape, TONMYA’s first-in-class status and unique sublingual delivery mechanism provide significant competitive differentiation, positioning Tonix Pharmaceuticals to capture substantial market share in a therapeutic area that has remained largely unchanged for over a decade.

Discover more fibromyalgia pipeline therapies and the clinical development progress they are making @ Fibromyalgia Clinical Pipeline.

Broader TONMYA Therapeutic Pipeline

Beyond fibromyalgia, Tonix Pharmaceuticals is investigating TNX-102 SL (now TONMYA) for additional indications, including acute stress reaction, posttraumatic stress disorder, and Long COVID-associated multi-site pain, potentially expanding its market opportunity significantly.

Industry Expert Perspective

Dr. Andrea Chadwick, M.D., MSc, FASA, at the University of Kansas Health System, commented on the novel administration approach: “Treatments that are processed through the liver can result in metabolites that could affect a medicine’s efficacy and safety over time. TONMYA is administered sublingually, which is designed to reduce pain quickly and durably with a tolerable safety profile.”

Learn more about what other Industry experts are saying about TONMYA FDA Approval and how it will impact the fibromyalgia treatment market @ Key Opinion Leaders on Fibromyalgia Market.

Looking Forward

The TONMYA approval represents a paradigm shift in fibromyalgia treatment and demonstrates the potential for innovative drug delivery approaches to address complex chronic pain conditions. Delveinsight’s analysts underline that as the pharmaceutical industry continues to focus on patient-centric therapeutic solutions, TONMYA’s success may pave the way for similar innovations in other underserved therapeutic areas.

Table of Contents

1. Key Insights

2. Executive Summary of Fibromyalgia

3. Competitive Intelligence Analysis for Fibromyalgia

4. Fibromyalgia Market Overview at a Glance

5. Fibromyalgia: Disease Background and Overview

6. Fibromyalgia Patient Journey

7. Fibromyalgia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Fibromyalgia Unmet Needs

10. Key Endpoints of Fibromyalgia Treatment

11. Fibromyalgia Marketed Products

12. Fibromyalgia Emerging Therapies

13. Fibromyalgia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Fibromyalgia

17. KOL Views

18. Fibromyalgia Market Drivers

19. Fibromyalgia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight Business Research

DelveInsight is a leading business consultant and market research firm in the pharmaceutical and healthcare sectors. The company provides comprehensive market intelligence, competitive analysis, and strategic consulting services to pharmaceutical companies, biotechnology firms, and healthcare organizations worldwide.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Annad
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fibromyalgia Treatment Landscape: FDA Approves TONMYA, First New Therapy in 15 Years | DelveInsight’s Perspective on Market Impact, Competitive Landscape and Other Pipeline Therapies

Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS, First Therapy in History | DelveInsight’s Perspective on Market Impact, Competitive Landscape and Pipeline Therapies

“Recurrent Respiratory Papillomatosis Market Insight, Epidemiology and Market Forecast report”
DelveInsight Business Research’s latest report highlights the transformative impact of the FDA’s approval of PAPZIMEOS (zopapogene imadenovec-drba) by Precigen, Inc. (NASDAQ: PGEN). This landmark approval marks the first FDA-approved therapy for recurrent respiratory papillomatosis in history, offering unprecedented hope for thousands of patients suffering from this rare and debilitating condition caused by human papillomavirus infection.

Key Recurrent Respiratory Papillomatosis Market Highlights

  • PAPZIMEOS approval represents a paradigm shift in the recurrent respiratory papillomatosis treatment landscape, given its first-in-class status as the only FDA-approved therapy for this condition.

  • Recurrent respiratory papillomatosis affects approximately 26K patients in the 7MM, with the US accounting for 66% of total cases.

  • Recurrent respiratory papillomatosis Companies: Precigen, Inc. (NASDAQ: PGEN), INOVIO Pharmaceuticals (NASDAQ: INO), Roche (SWX: ROG), Merck (NYSE: MRK), Gilead Sciences (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), and Novartis AG (NYSE: NVS), among others.

  • The recurrent respiratory papillomatosis market size was approximately USD 10.26 million in 2023 and is anticipated to grow at a CAGR of more than 40% through 2034.

Market Impact and Recurrent Respiratory Papillomatosis Patient Population

According to DelveInsight’s Recurrent Respiratory Papillomatosis Market Insight, Epidemiology and Market Forecast report, recurrent respiratory papillomatosis represents a significant unmet medical need with approximately 26K diagnosed prevalent cases across the 7MM countries. In 2023, the US represented the largest share of the diagnosed recurrent respiratory papillomatosis patients, accounting for approximately 66% of the total cases in 7MM, followed by EU4 and the UK (24%) and Japan (10%).

The condition is a rare, chronic disease characterized by the growth of benign tumors (papillomas) in the respiratory tract, particularly affecting the larynx and vocal cords. These growths, caused primarily by human papillomavirus (HPV) types 6 and 11, can obstruct the airway, leading to voice changes, breathing difficulties, and requiring recurring surgeries. Recurrent respiratory papillomatosis manifests in two forms: juvenile-onset, typically diagnosed in early childhood, and adult-onset, appearing later in life.

Among different age groups, the highest number of recurrent respiratory papillomatosis cases was observed in adults aged 18 years and above, followed by children aged 0-8 years, and adolescents aged 9-17 years.

Furthermore, the report highlights that the recurrent respiratory papillomatosis treatment market is anticipated to grow with a CAGR of more than 40.% by 2034, reflecting strong market expansion driven by the recent FDA approval, increasing recurrent respiratory papillomatosis epidemiology, and advancements in recurrent respiratory papillomatosis management approaches.

Download the Recurrent Respiratory Papillomatosis Market report to understand which other factors are driving the therapeutic market @ Recurrent Respiratory Papillomatosis Market Trends.

PAPZIMEOS Mechanism of Action and Treatment Approaches

PAPZIMEOS represents a first-in-class, non-replicating adenoviral vector-based immunotherapy, utilizing Precigen’s advanced gorilla adenovector technology within the AdenoVerse platform. This pioneering gene therapy enhances immune responses by targeting HPV types 6 and 11 through an optimized antigen design, administered via four subcutaneous injections over a 12-week interval. The therapy leverages high-capacity, low-seroprevalence gorilla adenovectors for effective gene delivery and immune modulation, offering patients a potential alternative to repeated surgical interventions.

“This long-awaited FDA approval represents a momentous milestone for the recurrent respiratory papillomatosis community,” said Kim McClellan, President of the Recurrent Respiratory Papillomatosis Foundation. “For the first time, adult patients with RRP have access to an FDA-approved therapy that offers the potential to reduce or even eliminate endless repeated surgeries.”

PAPZIMEOS Clinical Validation and Efficacy

The PAPZIMEOS FDA approval was based on compelling clinical evidence from Phase I/II pivotal trials demonstrating significant therapeutic benefit. Key clinical outcomes include 51.4% of patients achieving complete responses, defined as no surgical interventions for 12 months post-treatment. Remarkably, 83% of responders maintained outcomes through 24 months, demonstrating the durability of clinical benefit. This recurrent respiratory papillomatosis therapy was well-tolerated with no serious adverse events or long-term safety concerns identified across all studies, representing a significant advancement over the current surgical standard of care.

Recurrent Respiratory Papillomatosis Competitive Landscape and Market Positioning

PAPZIMEOS enters a treatment landscape that has historically lacked FDA-approved medical therapies, with the standard of care being surgical excision using microdebriders and photoangiolytic lasers. Prior to PAPZIMEOS approval, recurrent respiratory papillomatosis treatment options were limited to surgical interventions and off-label adjuvant treatments, including intralesional cidofovir, bevacizumab (Avastin) for anti-angiogenic therapy, interferon-alpha, and various HPV vaccines for prevention. The current treatment approach focuses primarily on symptom management and complication prevention, with no definitive cure existing until now.

PAPZIMEOS’s first-and-only approved therapy status provides unprecedented market exclusivity, protected by Breakthrough Therapy and Orphan Drug Designations from both the FDA and European Commission, granting seven years of market exclusivity. This positioning represents a complete transformation of the treatment paradigm for recurrent respiratory papillomatosis patients.

Explore the Recurrent Respiratory Papillomatosis Drug Battle: PAPZIMEOS vs. other emerging therapies. Discover how these breakthrough Recurrent Respiratory Papillomatosis therapies compare in efficacy, safety, cost, and market impact @ Recurrent Respiratory Papillomatosis Drugs Market.

Emerging Recurrent Respiratory Papillomatosis Pipeline Therapies

The recurrent respiratory papillomatosis treatment pipeline features INOVIO Pharmaceuticals (NASDAQ: INO) as the primary competitor developing INO-3107, a DNA medicine designed to elicit antigen-specific T cell responses against HPV-6 and HPV-11 proteins. INOVIO plans to submit its BLA for INO-3107 in mid-2025 under the FDA accelerated approval program following resolution of manufacturing challenges with the CELLECTRA device. Clinical data from INO-3107’s Phase 1/2 trial showed promising results with patients requiring fewer surgeries post-treatment and improving Complete Response rates over time.

Additional investigational approaches include anti-angiogenic targeted therapy with bevacizumab, mTOR inhibitors such as sirolimus, antiviral agents including cidofovir, and therapeutic vaccination strategies aimed at inducing immune elimination of HPV-infected epithelial cells. However, PAPZIMEOS maintains a significant first-mover advantage with its approved status, proven clinical efficacy, and comprehensive regulatory support.

Discover more recurrent respiratory papillomatosis pipeline therapies and the clinical development progress they are making @ Recurrent Respiratory Papillomatosis Clinical Pipeline.

Broader PAPZIMEOS Therapeutic Platform

Beyond recurrent respiratory papillomatosis, Precigen’s AdenoVerse platform technology underlying PAPZIMEOS has potential applications across multiple HPV-related conditions and other viral infections. The gorilla adenovector technology allows for repeat injections and has demonstrated scalable manufacturing capabilities, positioning Precigen to leverage this platform for additional therapeutic applications in oncology and rare diseases.

Industry Expert Perspective

Dr. Vijay Kumar, MD, Acting Director of the Office of Therapeutic Products in FDA’s Center for Biologics Evaluation and Research, commented: “This approval has the potential to transform the treatment landscape and offer lasting relief for recurrent respiratory papillomatosis patients who previously faced repeated surgeries to control symptoms of their disease.”

Learn more about what other Industry experts are saying about PAPZIMEOS FDA Approval and how it will impact the recurrent respiratory papillomatosis treatment market @ Key Opinion Leaders on Recurrent Respiratory Papillomatosis Market.

Looking Forward

The PAPZIMEOS approval represents a historic breakthrough in rare disease treatment and demonstrates the potential for gene therapy approaches to address previously untreatable conditions. DelveInsight’s analysts underline that the total market size of recurrent respiratory papillomatosis is anticipated to expand in the coming decade due to the expected impact of PAPZIMEOS and other emerging therapies. As the pharmaceutical industry continues to focus on rare disease therapeutics, PAPZIMEOS’s success establishes a precedent for innovative vector-based immunotherapies and may accelerate development in other HPV-related conditions and rare diseases with significant unmet medical needs.

Table of Contents

1. Key Insights

2. Executive Summary of Recurrent Respiratory Papillomatosis

3. Competitive Intelligence Analysis for Recurrent Respiratory Papillomatosis

4. Recurrent Respiratory Papillomatosis Market Overview at a Glance

5. Recurrent Respiratory Papillomatosis: Disease Background and Overview

6. Recurrent Respiratory Papillomatosis Patient Journey

7. Recurrent Respiratory Papillomatosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Recurrent Respiratory Papillomatosis Unmet Needs

10. Key Endpoints of Recurrent Respiratory Papillomatosis Treatment

11. Recurrent Respiratory Papillomatosis Marketed Products

12. Recurrent Respiratory Papillomatosis Emerging Therapies

13. Recurrent Respiratory Papillomatosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Recurrent Respiratory Papillomatosis

17. KOL Views

18. Recurrent Respiratory Papillomatosis Market Drivers

19. Recurrent Respiratory Papillomatosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight Business Research

DelveInsight is a leading business consultant and market research firm in the pharmaceutical and healthcare sectors. The company provides comprehensive market intelligence, competitive analysis, and strategic consulting services to pharmaceutical companies, biotechnology firms, and healthcare organizations worldwide.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recurrent Respiratory Papillomatosis Treatment Landscape: FDA Approves PAPZIMEOS, First Therapy in History | DelveInsight’s Perspective on Market Impact, Competitive Landscape and Pipeline Therapies

Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Migraine Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Migraine Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Migraine Treatment Landscape. Click here to read more @ Migraine Pipeline Outlook

Key Takeaways from the Migraine Pipeline Report

  • On 17 August 2025, Teva Branded Pharmaceutical Products R&D LLC announced a study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment in the pivotal study).
  • On 15 August 2025, Pfizer conducted a study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue.
  • On 15 August 2025, AbbVie announced a study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. The study will include 2 cohorts of participants – PK Cohort and Main Study (non-PK cohort)
  • DelveInsight’s Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.
  • The leading Migraine Companies such as ​Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
  • Promising Migraine Pipeline Therapies such as ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.

Stay informed about the cutting-edge advancements in Migraine Treatments. Download for updates and be a part of the revolution in Neurology care @ Migraine Clinical Trials Assessment

Migraine Emerging Drugs Profile

  • AXS-07: Axsome Therapeutics

AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.

  • STS-101: Satsuma Pharmaceuticals

STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration.

  • Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

  • TNX1900: Tonix Pharmaceuticals

TNX-1900(Oxytocin), Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication.

The Migraine pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Migraine with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Migraine Treatment.
  • Migraine Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Migraine Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Migraine market.

Get a detailed analysis of the latest innovations in the Migraine pipeline. Explore DelveInsight’s expert-driven report today! @ Migraine Unmet Needs

Migraine Companies

Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Migraine Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

Discover the latest advancements in Migraine Treatment by visiting our website. Stay informed about how we’re transforming the future of neurology @ Migraine Market Drivers and Barriers, and Future Perspectives

Scope of the Migraine Pipeline Report

  • Coverage- Global
  • Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics and others.
  • Migraine Pipeline Therapies- ALD403 (Eptinezumab), Ketorolac, Sumatriptan, divalproex sodium, Erenumab, GSK1838262, ALD403 and others.
  • Migraine Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Migraine Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Migraine Pipeline on our website @ Migraine Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Migraine: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Migraine– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. AXS-07: Axsome Therapeutics
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. STS-101: Satsuma Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Mid Stage Products (Phase II)
  14. TNX1900: Tonix Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Migraine Key Companies
  21. Migraine Key Products
  22. Migraine – Unmet Needs
  23. Migraine – Market Drivers and Barriers
  24. Migraine – Future Perspectives and Conclusion
  25. Migraine Analyst Views
  26. Migraine Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/migraine-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Migraine Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Parkinson’s disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma

“Parkinson’s disease psychosis Clinical Trials”
DelveInsight’s, “Parkinson’s disease psychosis – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Parkinson’s disease psychosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Parkinson’s disease psychosis pipeline includes over five key companies actively developing more than five investigational therapies.

Parkinson’s disease psychosis Overview:

Nonmotor symptoms have a major impact on the quality of life of Parkinson’s disease (PD) patients and their caregivers, and growing awareness among healthcare professionals highlights their significance. Psychosis is among the most common and debilitating nonmotor symptoms, affecting 20% to 70% of patients in advanced PD stages. It usually emerges in individuals with an intact sensorium during chronic disease progression and is often precipitated or exacerbated by medications. Recent research, however, points to additional risk factors, indicating a multifactorial origin and complex underlying mechanisms. The classification of early- versus late-onset psychosis, both generally and within PD, remains unstandardized, with some studies defining early-onset psychosis as occurring within 2–4 years of PD diagnosis.

Request for a detailed insights report on Parkinson’s disease psychosis pipeline insights

“Parkinson’s disease psychosis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson’s disease psychosis Therapeutics Market.

Key Takeaways from the Parkinson’s disease psychosis Pipeline Report

  • DelveInsight’s Parkinson’s disease psychosis pipeline report highlights an active landscape, with over five companies developing more than five investigational therapies for the treatment of Parkinson’s disease psychosis.

  • Leading companies in this space, including Vanda Pharmaceuticals, Sumitomo Pharma, and others, are advancing new drugs to enhance the treatment options for this condition. Promising pipeline candidates in various stages of development include Iloperidone, Ulotaront, and additional therapies.

  • AbbVie Inc. has been developing tavapadon, a selective D1/D5 receptor partial agonist, for early-stage Parkinson’s disease. In December 2025, AbbVie reported positive outcomes from a third Phase 3 trial, showing notable improvements in motor function, and plans to pursue FDA approval later in 2025.

Parkinson’s disease psychosis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Parkinson’s disease psychosis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson’s disease psychosis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson’s disease psychosis market.

Download our free sample page report on Parkinson’s disease psychosis pipeline insights

Parkinson’s disease psychosis Emerging Drugs

  • Iloperidone: Vanda Pharmaceuticals

  • Ulotaront: Sumitomo Pharma

Parkinson’s disease psychosis Companies

Over five leading companies are actively working on therapies for Parkinson’s disease psychosis, with Vanda Pharmaceuticals having a candidate in the most advanced stage, currently in Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Parkinson’s disease psychosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Parkinson’s disease psychosis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson’s disease psychosis Therapies and Key Companies: Parkinson’s disease psychosis Clinical Trials and advancements

Parkinson’s disease psychosis Pipeline Therapeutic Assessment

• Parkinson’s disease psychosis Assessment by Product Type

• Parkinson’s disease psychosis By Stage

• Parkinson’s disease psychosis Assessment by Route of Administration

• Parkinson’s disease psychosis Assessment by Molecule Type

Download Parkinson’s disease psychosis Sample report to know in detail about the Parkinson’s disease psychosis treatment market @ Parkinson’s disease psychosis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Parkinson’s disease psychosis Current Treatment Patterns

4. Parkinson’s disease psychosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Parkinson’s disease psychosis Late-Stage Products (Phase-III)

7. Parkinson’s disease psychosis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson’s disease psychosis Discontinued Products

13. Parkinson’s disease psychosis Product Profiles

14. Parkinson’s disease psychosis Key Companies

15. Parkinson’s disease psychosis Key Products

16. Dormant and Discontinued Products

17. Parkinson’s disease psychosis Unmet Needs

18. Parkinson’s disease psychosis Future Perspectives

19. Parkinson’s disease psychosis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Parkinson’s disease psychosis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson’s disease psychosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment, Pipeline | Vanda Pharmaceuticals, Sumitomo Pharma

Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Non‐cystic fibrosis bronchiectasis Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Non‐cystic fibrosis bronchiectasis pipeline landscape. It covers the Non Cystic Fibrosis Bronchiectasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Cystic Fibrosis Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non Cystic Fibrosis Bronchiectasis Treatment Landscape @ Non Cystic Fibrosis Bronchiectasis Pipeline Outlook

Key Takeaways from the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • On 17 August 2025, Verona Pharma plc announced a study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
  • DelveInsight’s Non Cystic Fibrosis Bronchiectasis pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Non Cystic Fibrosis Bronchiectasis treatment.
  • The leading Non Cystic Fibrosis Bronchiectasis Companies such as Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Promising Non Cystic Fibrosis Bronchiectasis Pipeline Therapies such as Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.

Stay informed about the cutting-edge advancements in Non Cystic Fibrosis Bronchiectasis treatments. Download for updates and be a part of the revolution in Respiratory Diseases Care @ Non Cystic Fibrosis Bronchiectasis Clinical Trials Assessment

Non Cystic Fibrosis Bronchiectasis Emerging Drugs Profile

  • Brensocatib: Insmed Incorporated

Brensocatib (INS1007 or AZD7986) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Insmed acquired the license for the treatment from AstraZeneca in 2016. Currently, the drug is in Phase III stage of its clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

  • HSK31858: Haisco Pharmaceutical Group Co., Ltd.

HSK31858 tablet is an oral, potent, and highly selective dipeptidyl peptidase 1 (DPP1) small molecule inhibitor independently developed by the Haisco Pharmaceutical. The main mechanism of action is that inhibiting DPP1 can inhibit the activation of neutrophils and the release of neutrophils to the circulatory system by inhibiting the activation of neutrophil NSP enzymes. It is clinically intended to be used for the treatment of lower respiratory tract diseases caused by bronchiectasis and acute lung injury/acute respiratory distress syndrome. The drug has completed phase I clinical trials in Australia and China, and now the phase II clinical trials of the project have completed the enrollment and administration of the first subject, and the project is progressing smoothly.

  • CSL 787: CSL Behring

CSL 787, is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease such as Non‐cystic fibrosis bronchiectasis (NCFB). Currently, the drug is being developed in the Phase I stage of Clinical trial evaluation for the treatment of Non‐cystic fibrosis bronchiectasis.

The Non Cystic Fibrosis Bronchiectasis Pipeline Report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non Cystic Fibrosis Bronchiectasis Treatment.
  • Non Cystic Fibrosis Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Non Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non Cystic Fibrosis Bronchiectasis market.

Learn more about Non Cystic Fibrosis Bronchiectasis Drugs opportunities in our groundbreaking Non Cystic Fibrosis Bronchiectasis research and development projects @ Non Cystic Fibrosis Bronchiectasis Unmet Needs

Non Cystic Fibrosis Bronchiectasis Companies

Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.

Non‐cystic fibrosis bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Non Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

Stay informed about how we’re transforming the future of Respiratory Disease @ Non Cystic Fibrosis Bronchiectasis Market Drivers and Barriers, and Future Perspectives

Scope of the Non Cystic Fibrosis Bronchiectasis Pipeline Report

  • Coverage- Global
  • Non Cystic Fibrosis Bronchiectasis Companies- Zambon SpA, AstraZeneca, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, CSL Behring and others.
  • Non Cystic Fibrosis Bronchiectasis Pipeline Therapies- Nebulized Ensifentrine Suspension; 3 mg, HSK31858, ARINA-1, Brensocatib 10 mg, RESP302, BAY85-8501 and others.
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non Cystic Fibrosis Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Non Cystic Fibrosis Bronchiectasis Pipeline on our website @ Non Cystic Fibrosis Bronchiectasis Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non‐cystic fibrosis bronchiectasis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non‐cystic fibrosis bronchiectasis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Brensocatib: Insmed Incorporated
  9. Mid Stage Products (Phase II)
  10. HSK31858: Haisco Pharmaceutical Group Co., Ltd.
  11. Early Stage Products (Phase I)
  12. CSL 787: CSL Behring
  13. Preclinical and Discovery Stage Products
  14. Drug name: Company name
  15. Inactive Products
  16. Non‐cystic fibrosis bronchiectasis Key Companies
  17. Non‐cystic fibrosis bronchiectasis Key Products
  18. Non‐cystic fibrosis bronchiectasis- Unmet Needs
  19. Non‐cystic fibrosis bronchiectasis- Market Drivers and Barriers
  20. Non‐cystic fibrosis bronchiectasis- Future Perspectives and Conclusion
  21. Non‐cystic fibrosis bronchiectasis Analyst Views
  22. Non‐cystic fibrosis bronchiectasis Key Companies
  23. 23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non Cystic Fibrosis Bronchiectasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics

“Lupus Nephritis Clinical Trials”
DelveInsight’s, “Lupus Nephritis – Pipeline Insight, 2025” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Lupus Nephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight reports that the Lupus Nephritis pipeline involves over 35 key companies actively developing more than 40 investigational therapies.

Lupus Nephritis Overview:

Lupus Nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disorder that disrupts immune tolerance, causing systemic autoimmunity and damage to multiple organs.

SLE affects roughly 7.4–159.4 individuals per 100,000, with a prevalence ranging from 1.4% to 21.9%. LN, a form of glomerulonephritis, leads to inflammation and scarring of the kidney’s filtering units (glomeruli) and, in some cases, the entire kidney. The condition is categorized into six histological classes, reflecting different severity levels. The most severe type, proliferative nephritis, results in kidney scarring and impaired function, which can progress to chronic kidney disease (CKD) or end-stage renal disease (ESRD), where the kidneys lose their ability to function completely.

Request for a detailed insights report on Lupus Nephritis pipeline insights

“Lupus Nephritis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.

Key Takeaways from the Lupus Nephritis Pipeline Report

  • DelveInsight’s Lupus Nephritis (LN) pipeline report highlights a dynamic landscape, with over 35 companies actively developing more than 40 investigational therapies for LN treatment.

  • Key players in this space include Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others, all working to advance new treatment options for LN. Promising pipeline candidates in various stages of development include Obinutuzumab, ADX-097, NKX019, and additional therapies.

  • In February 2024, the FDA granted Fast Track designation to AlloNK, an experimental natural killer (NK) cell therapy from Artiva Biotherapeutics, for use in combination with rituximab or obinutuzumab in lupus nephritis. This status is intended to accelerate development and review, enabling earlier patient access. AlloNK is designed to boost antibody-dependent cellular cytotoxicity (ADCC), potentially enhancing the effectiveness of existing antibody-based therapies.

Lupus Nephritis Pipeline Analysis

The report provides insights into:

  • The report provides detailed insights into the key companies that are developing therapies in the Lupus Nephritis Market.

  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.

  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Lupus Nephritis market.

Download our free sample page report on Lupus Nephritis pipeline insights

Lupus Nephritis Emerging Drugs

  • Obinutuzumab: Hoffmann-La Roche

  • ADX-097: Q32 Bio

  • NKX019: Nkarta

Lupus Nephritis Companies

Over 35 leading companies are actively working on therapies for Lupus Nephritis, with Hoffmann-La Roche having a candidate in the most advanced stage, currently in Phase III clinical trials.

DelveInsight’s report covers around 40+ products under different phases of clinical development like

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Lupus Nephritis Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Lupus Nephritis Therapies and Key Companies: Lupus Nephritis Clinical Trials and advancements

Lupus Nephritis Pipeline Therapeutic Assessment

• Lupus Nephritis Assessment by Product Type

• Lupus Nephritis By Stage

• Lupus Nephritis Assessment by Route of Administration

• Lupus Nephritis Assessment by Molecule Type

Download Lupus Nephritis Sample report to know in detail about the Lupus Nephritis treatment market @ Lupus Nephritis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Lupus Nephritis Current Treatment Patterns

4. Lupus Nephritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Lupus Nephritis Late-Stage Products (Phase-III)

7. Lupus Nephritis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Lupus Nephritis Discontinued Products

13. Lupus Nephritis Product Profiles

14. Lupus Nephritis Key Companies

15. Lupus Nephritis Key Products

16. Dormant and Discontinued Products

17. Lupus Nephritis Unmet Needs

18. Lupus Nephritis Future Perspectives

19. Lupus Nephritis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Lupus Nephritis Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Clinical Trials, Companies, Therapies, Treatment, Pipeline | Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics